ArticleNature2023
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 343 papers.
0numbers the graph read from it
0cells of the map it votes in
343citing papers in PubMed
70.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
343 citing papers in PubMed, 458 citations in OpenAlex.
- Integrative single-cell and spatial transcriptomic approaches to decipher the tumor microenvironment and therapeutic resistance in pancreatic cancer.Cancer biology & therapy · 2026Review
- Design, synthesis and biological evaluation of novel KRAS-G12D inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Review
- Daraxonrasib and the era of pan-RAS inhibition: mechanisms, clinical advances, and resistance landscapes.Experimental hematology & oncology · 2026Review
- Cancer-associated mutations in endometriosis reframe a benign disease through molecular oncology.Molecular oncology · 2026Review
- Personalized medicine, scientific revolution or self-serving illusion: viewpoint from EORTC-PAMM Group.ESMO open · 2026Review
- Engineered subtilisin protease degrades active KRAS in cancer cells leading to differential cell targeting.Research square · 2026Article
- KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors.Science advances · 2026Article
- Discovery of TCR-like antibodies to the KRAS G12D neoantigen via in silico-in vitro workflow.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity.Cancer immunology research · 2026Article
- Rewiring KRAS-driven cancers through the ubiquitin-proteasome system: therapeutic opportunities with a focus on deubiquitinase.Experimental & molecular medicine · 2026Review
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V.Journal of gastrointestinal cancer · 2026Review
- Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption.Nature communications · 2026Article
- Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeted KRASG12V Degradation In Vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis.Cancer research · 2026Article
- Deciphering the Molecular Landscape of Squamous Cell Carcinoma of the Anal Canal: From Biology to Precision Oncology.Cancers · 2026Review
- Brønsted-basic small molecules activate GTP hydrolysis in KRAS-Q61 mutants.Nature chemical biology · 2026Article
- A dual assault on KRAS.Nature chemical biology · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
283 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors at 2 institutions in 2 countries.
Dongsung Kim *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4152-628X
Lorenz Herdeis *Boehringer Ingelheim, Vienna, Austria.ORCID 0000-0001-5867-0216
Dorothea Rudolph *Boehringer Ingelheim, Vienna, Austria.
Yulei ZhaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2242-3843
Jark BöttcherBoehringer Ingelheim, Vienna, Austria.ORCID 0000-0003-2189-5926
Alberto VidesHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carlos I Ayala-SantosHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yasin PourfarjamHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Antonio Cuevas-NavarroHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6208-6944
Jenny Y XueHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1192-1836
Andreas MantoulidisBoehringer Ingelheim, Vienna, Austria.
Joachim BrökerBoehringer Ingelheim, Vienna, Austria.
Tobias WunbergBoehringer Ingelheim, Vienna, Austria.
Otmar SchaafBoehringer Ingelheim, Vienna, Austria.
Johannes PopowBoehringer Ingelheim, Vienna, Austria.
Bernhard WolkerstorferBoehringer Ingelheim, Vienna, Austria.
Katrin Gabriele KropatschBoehringer Ingelheim, Vienna, Austria.
Rui QuAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ben SangHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chuanchuan LiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Darryl B McConnellBoehringer Ingelheim, Vienna, Austria.ORCID 0000-0002-2537-3458
Norbert KrautBoehringer Ingelheim, Vienna, Austria.ORCID 0000-0003-3941-7105
Piro LitoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. litop@mskcc.org.ORCID 0000-0003-2196-3503
Boehringer Ingelheim (Austria) · ATMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2007 to 2026
$31.2MDissecting KRAS oncoprotein signaling with small molecule inhibitorsR01CA230745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2018 to 2026
$3.8MStudies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistanceR01CA230267 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LITO, PIRO · 2019 to 2023
$2.0MMechanisms of adaptation and resistance to emerging therapies for lung cancerR01CA279264 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2023 to 2026
$2.0MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA230267NCI NIH HHS R01 CA230745NCI NIH HHS R01 CA279264
Abstract
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C in its inactive conformation and suppress tumour growth in patients
Indexed as
NeoplasmsProto-Oncogene Proteins p21(ras)Signal TransductionAnimalsBody WeightCell DivisionEnzyme ActivationMiceMonomeric GTP-Binding ProteinsMutationNucleotidesSubstrate SpecificityHras protein, mouseMonomeric GTP-Binding ProteinsNras protein, mouseNucleotidesProto-Oncogene Proteins p21(ras)
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.